Insights
Perspectives on Governance, Accountability & Clinical Development
Kieran Engels writes about the structural patterns that shape clinical development outcomes – and the governance decisions that determine whether programs succeed or fail.
The Age of Accountability
The Age of Accountability resets biotech priorities: clarity of intent, explicit ownership, delivery that matches promise. Speed without control is crash risk. Accountability builds confident acceleration.
Read Article →
-
The Hidden Cost of Poor Governance
Poor governance creates hidden costs: scope drift, financial leakage, invisible rework, leadership fatigue, and slowed delivery. The fix requires clarity in strategy, explicit priorities, documented…
-
Governance Underinvestment, The Pennywise Problem in Clinical Development
Governance underinvestment looks like cost savings. It generates multiples in downstream rework, scope drift, and leadership overhead. Governance isn’t overhead. It’s the system that prevents…
-
Risk as a Powerful Tool in Clinical Development
Risk is information, not threat. Sponsors who read risk signals early and diagnose what they reveal about governance can prevent costly downstream rework and move…
-
Five Signs Your Vendor Governance Framework Needs Redesigning
Vendor underperformance is often a governance failure. Learn five diagnostic signs that your framework needs redesigning before replacing your vendor.